



ATTORNEYS AT LAW



Robert Greene Sterne	Jeffrey T. Helvey	Tracy L. Muller	W. Blake Coblenz*
Jorge A. Goldstein	Eldora L. Ellison	Jon E. Wright	James Pohl*
David K.S. Cornwell	Thomas C. Fiala	LuAnne M. DeSantis	John T. Haran
Robert W. Esmond	Donald R. Banowitz	Ann E. Summerfield	Mark W. Rygiel
Tracy-Gene G. Durkin	Peter A. Jackman	Helene C. Carlson	Cynthia M. Bouchez
Michele A. Cimbala	Jeffrey S. Weaver	Gaby L. Longsworth	Timothy A. Doyle
Michael B. Ray	Brian J. Del Buono	Lori A. Gordon	Karen R. Markowicz
Robert E. Sokohl	Mark Fox Evans	Laura A. Vogel	Matthew J. Dowd
Eric K. Steffe	Edward W. Yee	Bryan S. Wade	Katrina Yujian Pei Quach
Michael Q. Lee	Vincent L. Capuano	Bashir M.S. Ali	Bryan L. Skelton
Steven R. Ludwig	Virgil Lee Beaston	Shannon A. Carroll	Robert A. Schwartzman
John M. Cover	Theodore A. Wood	Anbar F. Khal	Victoria S. Rutherford
Robert C. Millonig	Elizabeth J. Haanes	Michelle K. Holoubek	Simon J. Elliott
Donald J. Featherstone	Joseph S. Ostroff	Marsha A. Rose	Julia A. Heider
Timothy J. Shea, Jr	Frank R. Cottingham	Young Tang	Mita Mukherjee
Michael V. Messinger	Daniel A. Klein	Christopher J. Walsh	
Judith U. Kim	Jason D. Eisenberg		
Patrick E. Garrett	Michael D. Specht		

Scott M. Woodhouse
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer

Registered Patent Agents*

Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland

*Admitted only in Virginia

*Practice Limited to
Federal Agencies

October 18, 2006

WRITER'S DIRECT NUMBER:
(202) 772-8525

INTERNET ADDRESS:
BRIAND@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1645

Mail Stop: Amendment

Re: U.S. Utility Patent Appl. No. 10/550,580; § 371 Date: September 23, 2005
 U.S. National Phase of Intl. Appl. No. PCT/EP04/003163
 International Filing Date: March 25, 2004
 For: **HIV-Peptide-Carrier-Conjugates**
 Inventors: Martin F. BACHMANN *et al.*
 Our Ref: 1700.0610001/BJD/WBC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. Form PTO-1449 (9 pages) citing seventy (70) documents (AA1-AD3 and AL1-AO9);
3. Copies of forty-four (44) cited documents (AL1-AP1; AL2-AP2; AL3-AP3; AL4-AP4; AL5-AP5; AL6-AP6; AL7-AP7; AL8-AP8; AL9-AO9);
4. Form PTO/SB/08B (9 pages) citing eighty-six (86) documents (NPL1-NPL86);
5. Copies of eighty-six (86) cited documents (NPL1-NPL10; NPL11-NPL20; NPL21-NPL30; NPL31-NPL40; NPL41-NPL50; NPL51-NPL60; NPL61-NPL70; NPL71-NPL80; and NPL81-NPL86); and
6. One (1) Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
October 18, 2006
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

BJD/WBC:cpn
Enclosures

596538_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Martin F. BACHMANN *et al.*

Appl. No.: 10/550,580

(U.S. National Phase of Intl. Appl. No.
PCT/EP04/003163)

Filed: September 23, 2005
(Int'l Filing Date: March 25, 2004)

For: **HIV-Peptide-Carrier-Conjugates**

Confirmation No.: 8355

Art Unit: 1645

Examiner: *To Be Assigned*

Atty. Docket: 1700.0610001/BJD/WBC

Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO-1449 and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **AL1** to **AO9** and **NPL1** to **NPL86** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, **AA1** to **AD3**, cited on the attached IDS Form, PTO-1449, are not submitted.

In accordance with 37 C.F.R. § 1.97(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents **AN1** and **AP3** cited on Form PTO 1449:

Document **AN1**, EP 0 201 416 B1, is in a foreign language. An English language abstract of document **AN1** is attached as **NPL86**.

Document **AP3**, WO 99/28478 A1, is in a foreign language. An English language abstract of document **AP3** is provided on the face page of the document.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications, which are directed to related technical subject matter:

Application No. 10/112,653, inventors Krieg *et al.*, filed March 29, 2002; published on March 13, 2003 as U.S. Publication No. 2003/0050268 A1; listed as Document **AC3**; and

Application No. 09/789,649, inventors Valmori *et al.*, filed February 21, 2001; published on May 1, 2003 as U.S. Publication No. 2003/0082804; listed as Document **AD3**.

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.




Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

Date: Oct. 18, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

588033_1



ATTY. DOCKET NO. 1700.0610001/BJD/WBC	APPLICATION NO. 10/550,580					
FIRST NAMED INVENTOR Bachmann, M.						
FILING DATE September 23, 2005	ART UNIT 1645					
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA1	4,722,840	02/02/1988	Valenzuela et al.			09/19/1985
AB1	4,959,314	09/25/1990	Mark et al.			02/07/1985
AC1	5,143,726	09/01/1992	Thornton et al.			11/20/1989
AD1	5,334,394	08/02/1994	Kossovsky et al.			01/04/1993
AE1	5,565,548	10/15/1996	Neurath et al.			03/15/1993
AF11	5,698,424	12/16/1997	Mastico et al.			06/26/1992
AG1	5,844,075	12/01/1998	Kawakami et al.			04/05/1995
AH1	5,871,747	02/16/1999	Gengoux-Sedlik et al.			09/13/1993
AI1	5,874,560	02/23/1999	Kawakami et al.			04/22/1994
AJ1	5,935,821	08/10/1999	Chatterjee et al.			11/21/1996
AK1	5,939,598	08/17/1999	Kucherlapati et al.			07/30/1992
FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL1	EP 0 038 154 B1	10/21/1981	Europe			Yes No
AM1	EP 0 385 610 B1	09/05/1990	Europe			Yes No
AN1	EP 0 201 416 B1	04/10/1991	Europe			X Yes No
AO1	EP 0 421 635 A1	04/10/1991	Europe			Yes No
AP1	WO 92/13081 A1	08/06/1992	WIPO			Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)						
AR						
AS						
AT						
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 1700.0610001/BJD/WBC	APPLICATION NO. 10/550,580
		FIRST NAMED INVENTOR Bachmann, M.	
		FILING DATE September 23, 2005	ART UNIT 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2	5,994,523	11/30/1999	Kawakami et al.			01/16/1998
	AB2	6,025,470	02/15/2000	Valmori et al.			06/23/1997
	AC2	6,231,864 B1	05/15/2001	Birkett			02/11/1999
	AD2	6,270,778 B1	08/07/2001	Kawakami et al.			03/12/1999
	AE2	6,277,956 B1	08/21/2001	Valmori et al.			04/16/1998
	AF2	6,326,200 B1	12/04/2001	Valmori et al.			06/18/1998
	AG2	6,368,857 B1	04/09/2002	Valmori et al.			10/05/1999
	AH2	6,380,364 B1	04/30/2002	Mueller et al.			10/06/1999
	AI22	6,384,190 B1	05/07/2002	Valmori et al.			12/14/1999
	AJ2	6,537,560 B1	03/25/2003	Kawakami et al.			05/05/1998
	AK2	6,627,202 B2	09/30/2003	Murray			06/04/2001

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	EP 0 578 293 A1	01/12/1994	Europe			Yes No
	AM2	WO 94/15585	07/21/1994	WIPO			Yes No
	AN2	WO 95/29193 A2	11/02/1995	WIPO			Yes No
	AO2	WO 96/30523 A2	10/03/1996	WIPO			Yes No
	AP2	EP 0 677 111 B1	10/18/1995	Europe			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR		
AS		
AT		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		ATTY. DOCKET NO. 1700.0610001/BJD/WBC	APPLICATION NO. 10/550,580
FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		FIRST NAMED INVENTOR Bachmann, M.	
		FILING DATE September 23, 2005	ART UNIT 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3	6,719,978 B2	04/13/2004	Schiller et al.			04/13/2001
	AB3	6,965,017 B2	11/15/2005	Kawakami et al.			07/03/2001
	AC3	2003/0050268 A1	03/13/2003	Krieg et al.			03/29/2002
	AD3	2003/0082804 A1	05/01/2003	Valmori et al.			02/21/2001
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL3	WO 98/40100 A1	09/17/1998	WIPO			Yes No
	AM3	WO 98/50071 A1	11/12/1998	WIPO			Yes No
	AN3	WO 98/49195 A1	11/05/1998	WIPO			Yes No
	AO3	WO 98/58751 A1	12/30/1998	WIPO			Yes X No
	AP3	WO 99/28478 A1	06/10/1999	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1700.0610001/BJD/WBC		APPLICATION NO. 10/550,580			
		FIRST NAMED INVENTOR Bachmann, M.					
		FILING DATE September 23, 2005		ART UNIT 1645			
		U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL4	WO 99/40934 A1	08/19/1999	WIPO			Yes No
	AM4	WO 99/57289 A2	11/11/1999	WIPO			Yes No
	AN4	WO 00/23955 A1	04/27/2000	WIPO			Yes No
	AO4	WO 00/32227 A2	06/08/2000	WIPO			Yes No
	AP4	WO 00/37610 A2	06/29/2000	WIPO			Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR						
	AS						
	AT						
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1700.0610001/BJD/WBC		APPLICATION NO. 10/550,580			
		FIRST NAMED INVENTOR Bachmann, M.					
		FILING DATE September 23, 2005		ART UNIT 1645			
		U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL5	WO 00/39304 A2	07/06/2000	WIPO			Yes No
	AM5	WO 00/50461 A1	08/31/2000	WIPO			Yes No
	AN5	WO 00/62800 A2	10/26/2000	WIPO			Yes No
	AO5	WO 01/16320 A1	03/08/2001	WIPO			Yes No
	AP5	WO 01/22972 A2	04/05/2001	WIPO			Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR						
	AS						
	AT						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO. 1700.0610001/BJD/WBC	APPLICATION NO. 10/550,580
		FIRST NAMED INVENTOR Bachmann, M.	FILING DATE September 23, 2005
		ART UNIT 1645	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL6	WO 01/22990 A2	04/05/2001	WIPO			Yes No
	AM6	WO 01/56603 A1	08/09/2001	WIPO			Yes No
	AN6	WO 01/58478 A1	08/16/2001	WIPO			Yes No
	AO6	WO 01/77158 A1	10/18/2001	WIPO			Yes No
	AP6	WO 01/85208 A2	11/15/2001	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTY. DOCKET NO. 1700.0610001/BJD/WBC		APPLICATION NO. 10/550,580		
			FIRST NAMED INVENTOR Bachmann, M.				
			FILING DATE September 23, 2005		ART UNIT 1645		
			U.S. PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL7	WO 01/98333 A2	12/27/2001	WIPO			Yes No
	AM7	WO 02/14478 A2	02/21/2002	WIPO			Yes No
	AN7	WO 02/053141 A2	07/11/2002	WIPO			Yes No
	AO7	WO 02/056905 A2	07/25/2002	WIPO			Yes No
	AP7	WO 02/056907 A2	07/25/2002	WIPO			Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR						
	AS						
	AT						
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1700.0610001/BJD/WBC		APPLICATION NO. 10/550,580			
		FIRST NAMED INVENTOR Bachmann, M.					
		FILING DATE September 23, 2005		ART UNIT 1645			
		U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL8	WO 03/024480 A2	03/27/2003	WIPO			Yes No
	AM8	WO 03/024481 A2	03/27/2003	WIPO			Yes No
	AN8	WO 03/031466 A2	04/17/2003	WIPO			Yes No
	AO8	WO 03/039225 A2	05/15/2003	WIPO			Yes No
	AP8	WO 03/040164 A2	05/15/2003	WIPO			Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR						
	AS						
	AT						
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 1700.0610001/BJD/WBC		APPLICATION NO. 10/550,580		
		FIRST NAMED INVENTOR Bachmann, M.				
		FILING DATE September 23, 2005		ART UNIT 1645		
		U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL9 WO 03/059386 A2	07/24/2003	WIPO			Yes No
	AM9 WO 2004/000351 A1	12/31/2003	WIPO			Yes No
	AN9 WO 04/007538 A2	01/22/2004	WIPO			Yes No
	AO9 WO 2004/016282 A1	02/26/2004	WIPO			Yes No
	AP					Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)						
	AR					
	AS					
	AT					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						

OCT. 18 2006

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet 1 of 9

Complete if Known

Application Number	10/550,580
Filing Date	September 23, 2005
First Named Inventor	Martin F. BACHMANN
Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket Number	1700.0610001/BJD/WBC

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL1	Adams, S.E., <i>et al.</i> , "The expression of hybrid HIV:Ty virus-like particles in yeast," <i>Nature</i> 329:68-70, Nature Publishing Group (1987)	
	NPL2	Addo, M.M., <i>et al.</i> , "Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed Against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load," <i>J. Virol.</i> 77:2081-2092, American Society for Microbiology (2003)	
	NPL3	Allen, T.M., <i>et al.</i> , "Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen," <i>J. Immunol.</i> 164:4968-4978, The American Association of Immunologists (2000)	
	NPL4	Altschul, S.F., <i>et al.</i> , "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> 215:403-410, Academic Press Limited (1990)	
	NPL5	Altschul, S.F., <i>et al.</i> , "Issues in searching molecular sequence databases," <i>Nature Genet.</i> 6:119-29, Nature Publishing Group (1994)	
	NPL6	Bachmann, M.F., and Zinkernagel, R.M., "Neutralizing Antiviral B Cell Responses," <i>Annu. Rev. Immunol.</i> 15:235-270, Annual Reviews Inc. (1997)	
	NPL7	Bachmann, M.F., and Zinkernagel, R., "The influence of virus structure on antibody responses and virus serotype formation," <i>Immunol. Today</i> 17:553-558, Elsevier Science Ltd. (1996)	
	NPL8	Bachmann, M.F., <i>et al.</i> , "Induction of protective cytotoxic T cells with viral proteins," <i>Eur. J. Immunol.</i> 24:2228-2236, VCH Verlagsgesellschaft mbH (1994)	
	NPL9	Bachmann, M.F., <i>et al.</i> , "Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8 ⁺ cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> 26:2595-2600, VCH Verlagsgesellschaft mbH (1996)	
	NPL10	Belsche, R.B., <i>et al.</i> , "Safety and immunogenicity of a Canarypox-Vectored Human Immunodeficiency Virus Type I Vaccine with or without gp120: A Phase 2 Study in Higher- and Lower-Risk Volunteers," <i>J. Infect. Dis.</i> 183:1343-1352, Infectious Diseases Society of America (2001)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/550,580
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	2	of	9	Attorney Docket Number	1700.0610001/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T ²
	NPL11	Berthet-Colominas, C., et al., "Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab," <i>EMBO J.</i> 18:1124-1136, European Molecular Biology Organization (1999)		
	NPL12	Borisova, G., et al., "Hybrid Hepatitis B Virus Nucleocapsid Bearing an Immunodominant Region from Hepatitis B Virus Surface Antigen," <i>J. Virol.</i> 67: 3696-3701, American Society for Microbiology (1993)		
	NPL13	Brown, W.L., et al., "RNA Bacteriophage Capsid-Mediated Drug Delivery and Epitope Presentation," <i>Intervirology</i> 45:371-80, S. Karger A.G. (July-December 2002)		
	NPL14	Buonaguro, L., et al., "High efficient production of Pr55 ^{gag} virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A," <i>Antiviral Res.</i> 49:35-47, Elsevier Science B.V. (2001)		
	NPL15	Clarke, B.E., et al., "Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria," <i>J. Gen. Virol.</i> 71:1109-1117, Society for General Microbiology (1990)		
	NPL16	DeClercq, E., "Interferon Induction by Polynucleotides, Modified Polynucleotides, and Polycarboxylates," <i>Methods Enzymol.</i> 78:227-36, Academic Press Ltd. (1981)		
	NPL17	Eckhardt, S.G., et al., "Hepatitis B Virus Core Antigen Has Two Nuclear Localization Sequences in the Arginine-Rich Carboxyl Terminus," <i>J. Virol.</i> 65:575 582, American Society for Microbiology (1991)		
	NPL18	Engleman, E.G., "Dendritic cells: Potential role in cancer therapy," <i>Cytotechnology</i> 25:1-8, Kluwer Academic Publishers (1997)		
	NPL19	Fehr, T., et al., "T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles," <i>Proc. Natl. Acad. Sci. USA</i> 95:9477-9481, The National Academy of Sciences (1998)		
	NPL20	Fehr, T., et al., "Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies," <i>J. Exp. Med.</i> 185:1785-92, The Rockefeller University Press (1997)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/550,580
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	3	of	9	Attorney Docket Number	1700.0610001/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T ²
	NPL21	Fitchen, J., et al., "Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response," <i>Vaccine</i> 13:1051-107, Elsevier Science Ltd. (1995)		
	NPL22	Franken, P., et al., "HIV-1 Nef protein: Purification, crystallizations, and preliminary X-ray diffraction studies," <i>Protein Sci.</i> 6:2681-2683, Cold Spring Harbor Laboratory Press (1997)		
	NPL23	Gerber, S., et al., "Human Papillomavirus Virus-Like Particles are Efficient Oral Immunogens when Coadministered with <i>Escherichia coli</i> Heat-Labile Enterotoxin Mutant R192G or CpG DNA," <i>J. Virol.</i> 75:4752-4760, American Society for Microbiology (2001)		
	NPL24	Geysen, H.M., et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," <i>Proc. Natl. Acad. Sci. USA</i> 81:3998-4002, National Academy of Sciences (1984)		
	NPL25	Gilbert, S.C., et al., "A protein particle vaccine containing multiple malaria epitopes," <i>Nat. Biotechnol.</i> 15:1280-1284, Nature America Publishing (1997)		
	NPL26	Gluckman, J.C., et al., "In vitro generation of human dendritic cells and cell therapy," <i>Cytokines Cell. Mol. Ther.</i> 3:187-196, Martin Dunitz Ltd. (1997)		
	NPL27	Goldberg, A.L., et al., "The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides," <i>Mol. Immunol.</i> 39:147-164, Elsevier Science Ltd. (October 2002)		
	NPL28	Golmohammadi, R., et al., "The crystal structure of bacteriophage Q beta at 3.5 Å resolution," <i>Structure</i> 4:543-54, Current Biology Ltd. (1996)		
	NPL29	Hanke, T., and McMichael, A.J., "Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya," <i>Nat. Med.</i> 6:951-955, Nature America Inc. (2000)		
	NPL30	Harding, C.V., and Song, R., "Phagocytic Processing of Exogenous Particulate Antigens by Macrophages for Presentation by Class I MHC Molecules," <i>J. Immunol.</i> 153:4925-4933, The American Association of Immunologists (1994)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/550,580
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	4	of	9	Attorney Docket Number	1700.0610001/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL31	Huston, J.S., <i>et al.</i> , "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins," <i>Methods Enzymol.</i> 203:46-88, Academic Press, Inc. (1991)	
	NPL32	Jegerlehner, A., <i>et al.</i> , "A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses," <i>Vaccine</i> 20:3104-3112, Elsevier Science Ltd. (August 2002)	
	NPL33	Jin, X., <i>et al.</i> , "Dramatic Rise in Plasma Viremia After CD8 ⁺ T Cell Depletion in Simian Immunodeficiency Virus-infected Macaques," <i>J. Exp. Med.</i> 189:991-8, The Rockefeller University Press (1999)	
	NPL34	Kaisho, T., and Akira, S., "Toll-like receptors as adjuvant receptors," <i>Biochim. Biophys. Acta.</i> 1589:1-13, Elsevier Science B.V. (February 2002)	
	NPL35	Kang, C.Y., <i>et al.</i> , "Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-Like Particles," <i>Biol. Chem.</i> 380:353-364, Walter De Gruyter (1999)	
	NPL36	Klinman, D.M., <i>et al.</i> , "Immunotherapeutic Applications of CpG-Containing Oligodeoxynucleotides," <i>Drug News Perspect.</i> 13:289-296, Prous Science (2000)	
	NPL37	Klovins, J., <i>et al.</i> , "Nucleotide sequence of a ssRNA phage from <i>Acinetobacter</i> : kinship to coliphages," <i>J. Gen. Virol.</i> 83:1523-1533, SGM (June 2002)	
	NPL38	Kovacsics-Bankowski, M., <i>et al.</i> , "Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages," <i>Proc. Natl. Acad. Sci. USA</i> 90:4942-4946, The National Academy of Sciences (1993)	
	NPL39	Kozlovska, T.M., <i>et al.</i> , "Recombinant RNA phage Q β capsid particles synthesized and self-assembled in <i>Escherichia coli</i> ," <i>Gene</i> 137:133-137, Elsevier Science Publishers B.V. (1993)	
	NPL40	Kozlovska, T. M., <i>et al.</i> , "RNA phage Q β Coat Protein as a Carrier for Foreign Epitopes," <i>Intervirology</i> 39:9-15, S. Karger A.G. (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/550,580
Sheet	5	of	9	Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1645
				Examiner Name	To Be Assigned
				Attorney Docket Number	1700.0610001/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL41	Kratz, P.A., <i>et al.</i> , "Native display of complete foreign protein domains on the surface of hepatitis B virus capsids," <i>Proc. Natl. Acad. Sci. USA</i> 96:1915-1920, National Academy of Sciences(1999)	
	NPL42	Krug, A., <i>et al.</i> , "Identification of CpG oligonucleotide sequences with high induction of IFN- α/β in plasmacytoid dendritic cells," <i>Eur. J. Immunol.</i> 31:2154-2163, Wiley-vch Verlag GmbH (2001)	
	NPL43	Kuramoto, E., <i>et al.</i> , "Oligonucleotide Sequences Required for Natural Killer Cell Activation," <i>Jpn. J. Cancer Res.</i> 83:1128-1131, Japanese Cancer Association (1992)	
	NPL44	Lechner, F., <i>et al.</i> , "Virus-Like Particles as a Modular System for Novel Vaccines," <i>Intervirology</i> 45:212-217, S. Karger A.G. (July-December 2002)	
	NPL45	Levy, H.B., "Induction of Interferon <i>in vivo</i> and <i>in vitro</i> by Polynucleotides and Derivatives, and Preparation of Derivatives," <i>Methods Enzymol.</i> 78:242-51, Academic Press, Inc. (1981)	
	NPL46	Li, Y., <i>et al.</i> , "Vaccination Against Angiogenesis-Associated Antigens: A Novel Cancer Immunotherapy Strategy," <i>Curr. Mol. Med.</i> 3:773-779, Bentham Science Publishers Ltd. (December 2003)	
	NPL47	Luo, L., <i>et al.</i> , "Induction of V3-Specific Cytotoxic T Lymphocyte Responses by HIV gag Particles Carrying Multiple Immunodominant V3 Epitopes of gp120," <i>Virology</i> 240:316-325, Academic Press (1998)	
	NPL48	Malling, H.-J., and Taudorf, E., "Allergenicity of alum-precipitated grass pollen extracts with different RAST activity," <i>Clin. Allergy</i> 17:399-404, Blackwell Scientific Publications (1987)	
	NPL49	Martin, S.J., <i>et al.</i> , "Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses," <i>AIDS</i> 7:1315-23, Current Science Ltd. (1993)	
	NPL50	McMichael, A.J., and Rowland-Jones, S.L., "Cellular immune responses to HIV," <i>Nature</i> 410:980-987, Macmillan Magazines Ltd. (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/550,580
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	6	of	9	Attorney Docket Number	1700.0610001/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T ²
	NPL51	Moingeon, P., "Strategies for designing vaccines eliciting Th1 responses in humans," <i>J. Biotechnol.</i> 98: 189-198, Elsevier Science B.V. (September 2002)		
	NPL52	Moss, R.B., et al., "In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides," <i>Vaccine</i> 18:1081-1087, Elsevier Science Ltd. (2000)		
	NPL53	Neirynck, S., et al., "A universal influenza A vaccine based on the extracellular domain of the M2 protein," <i>Nature Med.</i> 5:1157-1163, Nature America Inc. (1999)		
	NPL54	Nieland, J.D., et al., "Chimeric Papillomavirus Virus-Like Particles Induce a Murine Self-Antigen-Specific Protective and Therapeutic Antitumor Immune Response," <i>J. Cell. Biochem.</i> 73:145-152, Wiley-Liss, Inc. (1999)		
	NPL55	Notka, F., et al., "Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies," <i>Vaccine</i> 18:291-301, Elsevier Science Ltd. (2000)		
	NPL56	Nussbaum, A.K., et al., "PAProC: a prediction algorithm for proteasomal cleavages available on the WWW," <i>Immunogenetics</i> 53:87-94, Springer Verlag (2001)		
	NPL57	Oxenius, A., et al., "CpG-Containing Oligonucleotides are Efficient Adjuvants for Induction of Protective Antiviral Immune Responses with T-Cell Peptide Vaccines," <i>J. Virol.</i> 73:4120-4126, American Society for Microbiology (1999)		
	NPL58	Oxenius, A., et al., "Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection," <i>Proc. Natl. Acad. Sci. USA</i> 99: 13747-13752, National Academy of Sciences (October 2002)		
	NPL59	Pasek, M., et al., "Hepatitis B virus genes and their expression in <i>E. coli</i> ," <i>Nature</i> 282:575-579, Macmillan Journals Ltd. (1979)		
	NPL60	Pearson, W.R., "Rapid and Sensitive Sequence Comparison with FASTP and FASTA," <i>Methods Enzymol.</i> 183:63-98, Academic Press, Inc. (1990)		

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/550,580
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	7	of	9	Attorney Docket Number	1700.0610001/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T ²
	NPL61	Preikschat, P., et al., "Expression, assembly competence and antigenic properties of hepatitis B virus core gene deletion variants from infected liver cells," <i>J. Gen. Virol.</i> 80:1777-1788, SGM (1999)		
	NPL62	Pumpens, P., and Grens, E., "HBV Core Particles as a Carrier for B Cell/T Cell Epitopes," <i>Intervirology</i> 44:98-114, S. Karger AG (2001)		
	NPL63	Pushko, P., et al., "Analysis of RNA phage fr coat protein assembly by insertion, deletion and substitution mutagenesis," <i>Protein Eng.</i> 6:883-891, Oxford University Press (1993)		
	NPL64	Roth, J.F., "The yeast Ty virus-like particles," <i>Yeast</i> 16:785-95, John Wiley & Sons, Ltd. (2000)		
	NPL65	Rueda, P., et al., "Minor Displacements in the Insertion Site Provoke Major Differences in the Induction of Antibody Responses by Chimeric Parvovirus-like Particles," <i>Virology</i> 263:89-99, Academic Press (1999)		
	NPL66	Ruedl, C., et al., "Cross-presentation of virus-like particles by skinderived CD8 ⁻ dendritic cells: a dispensable role for TAP," <i>Eur. J. Immunol.</i> 32: 818-825, Wiley-VCH Verlag GmbH (March 2002)		
	NPL67	Salunke, D.M., et al., "Self-assembly of purified polyomavirus capsid protein VP1," <i>Cell</i> 46:895-904, Cell Press (1986)		
	NPL68	Sasnauskas, K., et al., "Yeast Cells Allow High-Level Expression and Formation of Polyomavirus-Like Particles," <i>Biol. Chem.</i> 380:381-386, Walter De Gruyter (1999)		
	NPL69	Shiver, J.W., et al., "Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity," <i>Nature</i> 415:331-335, Macmillan Magazines Ltd. (January 2002)		
	NPL70	Slepushkin, V.A., et al., "Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein," <i>Vaccine</i> 13:1399-402, Elsevier Science Ltd. (1995)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/550,580
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	8	of	9	Attorney Docket Number	1700.0610001/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T ²
	NPL71	Smiley, B.K., and Minion, F.C., "Enhanced readthrough of opal (UGA) stop codons and production of <i>Mycoplasma pneumoniae</i> P1 epitopes in <i>Escherichia coli</i> ," <i>Gene</i> 134:33-40, Elsevier Science Publishers B.V. (1993)		
	NPL72	Sparwasser, T., et al., "Immunostimulatory CpG-Oligodeoxynucleotides Cause Extramedullary Murine Hemopoiesis," <i>J. Immunol.</i> 162:2368-2374, American Association of Immunologists (1999)		
	NPL73	Steinman, R.M., "Dendritic cells and immune-based therapies," <i>Exp. Hematol.</i> 24:859-862, International Society for Experimental Hematology (1996)		
	NPL74	Storni, T., et al., "Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles," <i>J. Immunol.</i> 168(6):2880-2886, The American Association of Immunologists (March 2002)		
	NPL75	Taylor, K.M., et al., "Position-Dependent Processing of Peptides Presented on the Surface of Cowpea Mosaic Virus," <i>Biol. Chem.</i> 380:387-392, Walter De Gruyter (1999)		
	NPL76	Toes, R.E., et al., "Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products," <i>J. Exp. Med.</i> 194:1-12, The Rockefeller University Press (2001)		
	NPL77	Torrence, P.F., "Preparation of a Synthetic Polynucleotide Interferon Inducer," <i>Methods Enzymol.</i> 78:326-331, Academic Press Inc. (1981)		
	NPL78	Touze, A., et al., "Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells," <i>J. Gen. Virol.</i> 82:3005-3009, Society for General Microbiology (2001)		
	NPL79	Townsend, A., and Bodmer, H., "Antigen Recognition by Class I-Restricted T Lymphocytes," <i>Ann. Rev. Immunol.</i> 7:601-624, Annual Reviews Inc. (1989)		
	NPL80	Turner, B.G., and Summers, M.F., "Structural Biology of HIV," <i>J. Mol. Biol.</i> 285:1-32, Academic Press (1999)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/550,580
				Filing Date	September 23, 2005
				First Named Inventor	Martin F. BACHMANN
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	9	of	9	Attorney Docket Number	1700.0610001/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published		T ²
	NPL81	Van Schooten, W., <i>et al.</i> , "Biological properties of dendritic cells: implications to their use in the treatment of cancer," <i>Mol. Med. Today</i> 255:254-260, Elsevier Science Ltd. (1997)		
	NPL82	Vasiljeva, I., <i>et al.</i> , "Mosaic Q β coats as a new presentation model," <i>FEBS Lett.</i> 431:7-11, Federation of European Biochemical Societies (1998)		
	NPL83	Witte, L., <i>et al.</i> , "Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy," <i>Cancer Metastasis Rev.</i> 17:155-61, Kluwer Academic Publishers (1998)		
	NPL84	Yuan, T.T., <i>et al.</i> , "Subtype-Independent Immature Secretion and Subtype-Dependent Replication Deficiency of a Highly Frequent, Naturally Occurring Mutation of Human Hepatitis B Virus Core Antigen." <i>J. Virol.</i> 73:10122-10128, American Society for Microbiology (1999)		
	NPL85	Zhou, S., <i>et al.</i> , "Cys Residues of the Hepatitis B Virus Capsid Protein Are Not Essential for the Assembly of Viral Core Particles but Can Influence Their Stability," <i>J. Virol.</i> 66:5393-5398, American Society for Microbiology (1992)		
	NPL86	Dialog File 351, Accession No. 3908140, English language abstract for EP 0 201 416 B1		

587772_1

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.